Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in

Sarah Orfanos1,2, Ibrahim El Husseini1,2, Thomas Nahass1

  • 1Dept of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

ERJ Open Research
|October 12, 2020
PubMed